Concord Biotech IPO lists at 21.5% premium

Concord Biotech, a biopharmaceuticals company, makes a remarkable entry in the stock market with a premium listing. Zee Business's Anil Singhvi shares valuable insights for both long-term and short-term investors. Find out the target price and strategies for holding on to Concord Biotech shares in this market update.